Skip to main content

Table 3 Pearson correlation analysis among sleep scores (pooled data)

From: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

  MOS-Sleep Scale, SPI-I UPDD Sleep Interference Score CU-Q2oL Sleep Problems domain
Sleep outcome
 Baseline
  MOS-Sleep Scale, SPI-I
   r 1.00000 0.39454* 0.74655*
   n 970 970 847
  UPDD Weekly Sleep Interference Score
   r 0.39454* 1.00000 0.48848*
   n 970 975 848
  CU-Q2oL Sleep Problems domain
   r 0.74655* 0.48848* 1.00000
   n 847 848 848
 Week 12
  MOS-Sleep Scale, SPI-I
   r 1.00000 0.44790* 0.72307*
   n 828 809 722
  UPDD Weekly Sleep Interference Score
   r 0.44790* 1.00000 0.60849*
   n 809 827 707
  CU-Q2oL Sleep Problems domain
   r 0.72307* 0.60849* 1.00000
   n 722 707 724
 Week 24
  MOS-Sleep Scale, SPI-I
   r 1.00000 0.462952* 0.68932*
   n 494 475 435
  UPDD Weekly Sleep Interference Score
   r 0.46295* 1.00000 0.58334*
   n 475 726 418
  CU-Q2oL Sleep Problems domain
   r 0.68932* 0.58334* 1.00000
   n 435 418 437
  1. CU-Q 2 oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
  2. * p < 0.0001
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us